Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 24

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 24
---
 our consolidated financial statements and issuing an opinion on

<div align='center'>-14-</div>

the conformity of those audited consolidated financial statements with generally accepted accounting principles in the United States. Moss Adams discussed with the Audit Committee the adequacy of our internal control over financial reporting. The Audit Committee does not itself prepare financial statements or perform audits, and its members are not auditors or certifiers of Lineage’s financial statements. The Audit Committee also met on a quarterly basis with our independent registered public accounting firm during 2024 to review and discuss our consolidated financial statements for the quarter and the adequacy of internal control over financial reporting.

In the performance of its oversight function and in connection with the audited financial statements contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the Audit Committee:

reviewed and discussed the audited financial statements as of and for the fiscal year ended December 31, 2024 with our management and with representatives of Moss Adams;

discussed with representatives of Moss Adams the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“ PCAOB ”) and the SEC;

received and reviewed the written disclosures and the letter from Moss Adams required by applicable requirements of the PCAOB regarding Moss Adams’ communications with the Audit Committee concerning independence, and discussed with representatives of Moss Adams its independence from Lineage; and

based on the reviews and discussions described in the bullet points above, the Audit Committee unanimously recommended to our Board that the audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2024 for filing with the SEC.

The Audit Committee:

Deborah Andrews (Chair)

Michael H. Mulroy

Angus C. Russell

Don M. Bailey

<div align='center'>-15-

COMMITMENT TO CORPORATE RESPONSIBILITY AND SUSTAINABILITY</div>

Lineage is a clinical-stage biotechnology company developing novel allogeneic, or “off-the-shelf,”cell therapies for serious neurological and ophthalmic conditions. Our programs are based on our proprietary, cell-based technology platform and associated development, formulation, delivery and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are produced by applying directed differentiation processes to established, well characterized, and self-renewing pluripotent cell lines. These